PROK Share Price Performance
US$1.60
0.72 (82.61%)
Price US$1.60
Share Pricen/a
ProKidney Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
PROK Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
ProKidney Corp. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.49
- 100.00%
- -7,725.20%
- 0%
About PROK
- Founded
- 2015
- Employees
- 231
- CEO
- WebsiteView website
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
